MCID: FLL027
MIFTS: 66

Fallopian Tube Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Carcinoma

MalaCards integrated aliases for Fallopian Tube Carcinoma:

Name: Fallopian Tube Carcinoma 12 54 15 17 70
Fallopian Tube Cancer 12 20 36 54 15
Cancer of the Fallopian Tube 12 20
Carcinoma of Fallopian Tube 12 29
Neoplasm of Fallopian Tube 12 29
Fallopian Tube Neoplasms 44 70
Malignant Neoplasm of Fallopian Tube 70
Malignant Neoplasm of Uterine Tube 12
Malignant Tumour of Fallopian Tube 12
Malignant Tumor of Fallopian Tubes 58
Malignant Tumor of Fallopian Tube 12
Tumor, Fallopian Tube, Malignant 12
Tumor of the Fallopian Tube 12
Cancer of Fallopian Tubes 58
Fallopian Tube Neoplasm 12
Malignant Tubal Tumor 58
Fallopian Tube Ca 12
Tubal Cancer 58

Characteristics:

Orphanet epidemiological data:

58
malignant tumor of fallopian tubes
Prevalence: 1-9/100000 (Europe);

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:1963 DOID:1964
KEGG 36 H01554
ICD9CM 34 183.2
MeSH 44 D005185
ICD10 32 C57.0
ICD10 via Orphanet 33 C57.0
UMLS via Orphanet 71 C0153579 C0238122
Orphanet 58 ORPHA180242
UMLS 70 C0015558 C0153579 C0238122

Summaries for Fallopian Tube Carcinoma

GARD : 20 Fallopian tube cancer develops in the tubes that connect a woman's ovaries and uterus. It is very rare and accounts for only 1-2% of all gynecologic cancers. Fallopian tube cancer occurs when normal cells in one or both tubes change and grow in an uncontrolled way, forming a mass called a tumor. Cancer can begin in any of the different cell types that make up the fallopian tubes. The most common type is called adenocarcinoma (a cancer of cells from glands). Leiomyosarcoma (a cancer of smooth muscle cells) and transitional cell carcinoma (a cancer of the cells lining the fallopian tubes) are more rare. While some fallopian tube cancers actually begin in the tubes themselves, fallopian tube cancer is more often the result of cancer spreading from other parts of the body to the tubes. For example, the fallopian tubes are a common site of metastasis (spread) of cancers that started in the ovaries, uterus, endometrium, (the tissue lining the uterus) appendix, or colon. Women with fallopian tube cancer may experience symptoms, although some affected women may have no symptoms at all. The signs of fallopian tube cancer are often non-specific, meaning that they can also be signs of other medical conditions that are not cancer. Signs and symptoms of fallopian tube cancer can include: irregular or heavy vaginal bleeding (especially after menopause); occasional abdominal or pelvic pain or feeling of pressure; vaginal discharge that may be clear, white, or tinged with blood; and a pelvic mass or lump. Doctors use many tests to diagnose cancer of the fallopian tubes. Some of these tests may include: pelvic examination, transvaginal ultrasound, a blood test that measures the tumor marker CA-125, computed tomography (CT or CAT) scan, and magnetic resonance imaging (MRI). Fallopian tube cancer can be best treated when detected early. If the cancer has spread to the walls of the tubes or outside of the tubes, then there is a lower chance that the disease can be treated successfully. The stage of the cancer determines the type of treatment needed. Most women will need surgery and some will go on to have chemotherapy and/or radiation therapy.

MalaCards based summary : Fallopian Tube Carcinoma, also known as fallopian tube cancer, is related to intravenous leiomyomatosis and inflammatory breast carcinoma. An important gene associated with Fallopian Tube Carcinoma is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are ERK Signaling and Gene Expression. The drugs Paclitaxel and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include fallopian tube, ovary and uterus, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

Disease Ontology : 12 A female reproductive organ cancer that is located in fallopian tube.

KEGG : 36 Fallopian tube cancer is a rare, aggressive gynecologic malignancy. Recent genetic and immunohistochemical studies strongly suggest that high-grade serous adenocarcinoma (SAC) involving the ovary likely arises from distal fallopian tube epithelium, indicating that some ovarian cancers develop in the fallopian tube and are then spread to the ovary. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. It has been proposed that the p53 signature is the earliest step in the pathogenesis of fallopian tube cancer. In this model, tubal epithelium on the fimbria experiences genotoxic damage and, as a result, the secretory cell exhibits over-accumulation of p53 protein (p53 signature). There is also some evidence that BRCA-1 and BRCA-2 mutations and c-myc have a major role in tumorgenesis.

Wikipedia : 73 Primary fallopian tube cancer (PFTC), often just tubal cancer, is a malignant neoplasm that originates... more...

Related Diseases for Fallopian Tube Carcinoma

Diseases related to Fallopian Tube Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 396)
# Related Disease Score Top Affiliating Genes
1 intravenous leiomyomatosis 30.5 PGR ESR1
2 inflammatory breast carcinoma 30.5 PGR ESR1 ERBB2
3 cystadenocarcinoma 30.4 VEGFA TP53 PGR ERBB2 BRCA1
4 primary peritoneal carcinoma 30.4 VEGFA TP53 PGR ERBB2 BRCA2 BRCA1
5 ovarian serous cystadenocarcinoma 30.3 VEGFA TP53 PGR ERBB2
6 papillary serous adenocarcinoma 30.3 TP53 PGR PAX8 BRCA2 BRCA1
7 fallopian tube endometrioid adenocarcinoma 30.2 RAD51C PAX8 ERBB2
8 papillary adenocarcinoma 30.2 TP53 PGR ERBB2 BRCA2 BRCA1
9 breast fibroadenoma 30.2 TP53 PGR ESR1 ERBB2 BRCA1
10 mucinous adenocarcinoma 30.2 VEGFA TP53 PGR ESR1 ERBB2
11 papillary carcinoma 30.2 PGR PAX8 ESR1 ERBB2
12 cervix carcinoma 30.0 TP53 PGR PAX8 MYC ESR1 ERBB2
13 cystadenoma 29.9 PTEN PGR BRCA1
14 estrogen-receptor positive breast cancer 29.8 VEGFA TP53 PGR MYC ESR1 ERBB2
15 peripheral nervous system disease 29.8 VEGFA TP53 PTEN MYC ERBB2
16 endometriosis 29.8 VEGFA PTEN PGR MMP2 ESR1
17 carcinosarcoma 29.8 TP53 PTEN PGR PAX8 ERBB2
18 endometrial adenocarcinoma 29.7 VEGFA TP53 PTEN PGR ESR1 ERBB2
19 uterine carcinosarcoma 29.7 TP53 PTEN PGR ERBB2 BRCA1
20 cervical adenocarcinoma 29.7 TP53 PTEN MYC ESR1 ERBB2
21 wilms tumor 1 29.6 VEGFA TP53 PGR PAX8 MYC ESR1
22 serous cystadenocarcinoma 29.5 VEGFA TP53 PTEN PGR PAX8 MMP2
23 in situ carcinoma 29.5 TP53 PTEN PGR MYC ESR1 ERBB2
24 adenocarcinoma 29.1 VEGFA TP53 PTEN MYC MMP2 ERBB2
25 rhabdomyosarcoma 28.8 VEGFA TP53 PTEN MYC MMP2 ESR1
26 endometrial cancer 28.8 VEGFA TP53 PTEN PGR PAX8 MYC
27 lynch syndrome 28.4 TP53 RAD51D RAD51C PTEN PALB2 MRE11
28 hereditary breast ovarian cancer syndrome 28.2 TP53 RAD51D RAD51C PTEN PALB2 MRE11
29 ovarian cancer 26.9 WFDC2 VEGFA TP53 RAD51D RAD51C PTEN
30 fallopian tube adenocarcinoma 11.3
31 familiar fallopian tube carcinoma 11.3
32 fallopian tube adenosarcoma 11.2
33 fallopian tube transitional cell carcinoma 11.2
34 fallopian tube squamous cell carcinoma 11.2
35 fallopian tube leiomyosarcoma 11.2
36 fallopian tube carcinosarcoma 11.2
37 fallopian tube germ cell cancer 11.2
38 ovarian epithelial cancer 10.6
39 vaginal discharge 10.5
40 rare tumor 10.5
41 fallopian tube clear cell adenocarcinoma 10.4 BRCA2 BRCA1
42 scirrhous adenocarcinoma 10.4 PGR ERBB2
43 gastric papillary adenocarcinoma 10.4 TP53 ERBB2
44 lipid-rich breast carcinoma 10.4 PGR ERBB2
45 bartholin's gland adenoid cystic carcinoma 10.4 PGR ESR1
46 uterine corpus adenosarcoma 10.4 PGR ESR1
47 chronic tympanitis 10.4 PGR ESR1
48 anal carcinoma in situ 10.4 TP53 MYC
49 granulomatous endometritis 10.4 PGR ESR1
50 vulvar syringoma 10.4 PGR ESR1

Comorbidity relations with Fallopian Tube Carcinoma via Phenotypic Disease Network (PDN):


Ovarian Cancer

Graphical network of the top 20 diseases related to Fallopian Tube Carcinoma:



Diseases related to Fallopian Tube Carcinoma

Symptoms & Phenotypes for Fallopian Tube Carcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.24 BARD1 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 10.24 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 10.24 BARD1 BRCA1 BRCA2 PALB2
4 Decreased homologous recombination repair frequency GR00236-A-2 10.24 BARD1 BRCA1 BRCA2 PALB2
5 Decreased homologous recombination repair frequency GR00236-A-3 10.24 BARD1 BRCA1 BRCA2 PALB2
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.21 BARD1 BRCA1 BRCA2 MRE11 PALB2 PTEN
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.21 BRCA1 BRCA2 MRE11 PALB2 PTEN TP53
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.21 BARD1 BRCA1 BRCA2 MRE11 RAD51D TP53
9 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 10.19 BARD1 RAD51D TP53
10 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 10.19 BARD1 BRCA1 MYC PALB2 PTEN RAD51D
11 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 10.19 BARD1 BRCA1 BRCA2 MRE11 PALB2 RAD51D
12 Decreased viability with cisplatin GR00101-A-4 9.5 BARD1 BRCA1 BRCA2
13 Synthetic lethal with cisplatin GR00101-A-1 9.33 BARD1 BRCA1 BRCA2
14 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BARD1 BRCA1 BRCA2 MRE11 RAD51D

MGI Mouse Phenotypes related to Fallopian Tube Carcinoma:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 BRCA1 CDKN1B ERBB2 ESR1 MMP2 MRE11
2 embryo MP:0005380 10.5 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
3 growth/size/body region MP:0005378 10.5 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
4 cellular MP:0005384 10.49 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
5 homeostasis/metabolism MP:0005376 10.43 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
6 mortality/aging MP:0010768 10.43 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
7 behavior/neurological MP:0005386 10.42 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MRE11
8 endocrine/exocrine gland MP:0005379 10.37 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
9 hematopoietic system MP:0005397 10.31 BRCA1 BRCA2 CDKN1B ESR1 MMP2 MRE11
10 immune system MP:0005387 10.29 BRCA1 BRCA2 CDKN1B ESR1 MMP2 MRE11
11 nervous system MP:0003631 10.27 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
12 limbs/digits/tail MP:0005371 10.26 BRCA1 BRCA2 ERBB2 ESR1 MYC PALB2
13 neoplasm MP:0002006 10.25 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
14 integument MP:0010771 10.24 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MYC
15 digestive/alimentary MP:0005381 10.23 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MYC
16 craniofacial MP:0005382 10.19 CDKN1B ERBB2 MMP2 MYC PAX8 TEAD1
17 muscle MP:0005369 10.17 BRCA1 CDKN1B ERBB2 ESR1 MMP2 MYC
18 normal MP:0002873 10.07 BARD1 BRCA1 BRCA2 ERBB2 ESR1 MMP2
19 reproductive system MP:0005389 10 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
20 no phenotypic analysis MP:0003012 9.87 CDKN1B ESR1 MYC PAX8 PGR TP53
21 respiratory system MP:0005388 9.61 BRCA1 CDKN1B ERBB2 ESR1 MMP2 PTEN
22 skeleton MP:0005390 9.44 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MMP2

Drugs & Therapeutics for Fallopian Tube Carcinoma

Drugs for Fallopian Tube Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 348)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Sodium citrate Approved, Investigational Phase 3 68-04-2
6
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
7
Tamoxifen Approved Phase 3 10540-29-1 2733526
8
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
9
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
10
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
11
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
12
Selenious acid Approved, Investigational Phase 3 7783-00-8
13
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
14
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
15
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
16
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
17
Ifosfamide Approved Phase 3 3778-73-2 3690
18
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
19
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
20
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
21
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
22
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
23
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 5881
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
25
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
28
Oregovomab Investigational Phase 3 213327-37-8
29
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
30
Trebananib Investigational Phase 3 894356-79-7
31
Fosbretabulin Investigational Phase 2, Phase 3 222030-63-9 5351387
32 Combretastatin Investigational Phase 2, Phase 3 82855-09-2
33 Albumin-Bound Paclitaxel Phase 3
34 Carotenoids Phase 3
35 taxane Phase 3
36 Epothilones Phase 3
37 Epothilone B Phase 3
38 Vitamin B 6 Phase 3
39
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
40 Cola Phase 3
41 DHEA (Dehydroepiandrosterone) Phase 3
42 Anesthetics Phase 3
43 Narcotics Phase 3
44 Analgesics, Opioid Phase 3
45 Anesthetics, Intravenous Phase 3
46 Anesthetics, General Phase 3
47 Citrate Phase 3
48 Gastrointestinal Agents Phase 3
49 Protein Kinase Inhibitors Phase 3
50 Hormone Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 612)
# Name Status NCT ID Phase Drugs
1 An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice Recruiting NCT01932125 Phase 4 Bevacizumab
2 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
3 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
4 Feasibility of Intraoperative Given Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin During a Cytoreductive Surgery in Patients With Recurrent Ovarian, Peritoneal or Fallopian Tube Cancers Unknown status NCT03717610 Phase 3
5 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
6 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
7 Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. Unknown status NCT01628380 Phase 3
8 A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
9 SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers Completed NCT00098878 Phase 3 carboplatin
10 A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
11 Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy Completed NCT00003120 Phase 3 paclitaxel
12 A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone Vs. Delayed Treatment Based On Conventional Clinical Indicators Completed NCT00002895 Phase 3 chemotherapy
13 A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
14 A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
15 A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV Completed NCT00052468 Phase 3 TCG;TC
16 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
17 A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
18 A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma Completed NCT00003636 Phase 3 carboplatin;cisplatin
19 A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
20 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
21 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
22 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
23 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
24 Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
25 An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL) Completed NCT00989131 Phase 3 Paclical®;Taxol®
26 FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Completed NCT02631876 Phase 3 Mirvetuximab soravtansine;Paclitaxel;Pegylated liposomal doxorubicin;Topotecan
27 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
28 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
29 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
30 A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT01846611 Phase 3 Trabectedin;DOXIL;Dexamethasone;DOXIL
31 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
32 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
33 A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
34 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
35 A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
36 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
37 A Randomised Placebo-controlled Trial of Saracatinib (AZD0530) Plus Weekly Paclitaxel in Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
38 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Completed NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
39 The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
40 A Randomized Study of Chemotherapy Versus Hormonal Treatment in Patients With Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
41 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
42 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
43 Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT01704651 Phase 3 Alvimopan;Placebo
44 MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Recruiting NCT04209855 Phase 3 Mirvetuximab Soravtansine;Paclitaxel;Topotecan;Pegylated liposomal doxorubicin
45 SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Recruiting NCT04296890 Phase 3 Mirvetuximab Soravtansine
46 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (Collectively Referred to as Ovarian Cancer) Who Have Achieved Effective Response After First-line Platinum-containing Chemotherapy Recruiting NCT03709316 Phase 3 ZL-2306 (Nirapairb);Placebo Comparator
47 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer Recruiting NCT02859038 Phase 3
48 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
49 A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036) Recruiting NCT03740165 Phase 3 Placebo for pembrolizumab;Carboplatin;Paclitaxel;Olaparib;Placebo for olaparib;Docetaxel
50 Multi-center, Randomized Controlled, Phase III Trials to Evaluate the Safety and Effectiveness After Cycles Reduction of Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer Recruiting NCT03693248 Phase 3 Two cycles of neoadjuvant chemotherapy

Search NIH Clinical Center for Fallopian Tube Carcinoma

Cochrane evidence based reviews: fallopian tube neoplasms

Genetic Tests for Fallopian Tube Carcinoma

Genetic tests related to Fallopian Tube Carcinoma:

# Genetic test Affiliating Genes
1 Neoplasm of Fallopian Tube 29
2 Carcinoma of Fallopian Tube 29

Anatomical Context for Fallopian Tube Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Fallopian Tube Carcinoma:

19
Fallopian Tube

MalaCards organs/tissues related to Fallopian Tube Carcinoma:

40
Ovary, Uterus, T Cells, Colon, Smooth Muscle, Appendix, Breast

Publications for Fallopian Tube Carcinoma

Articles related to Fallopian Tube Carcinoma:

(show top 50) (show all 743)
# Title Authors PMID Year
1
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. 61 54
19141781 2009
2
Occult fallopian tube cancer in a patient with BRCA1 breast cancer. 61 54
18971141 2008
3
Microinvasive fimbrial fallopian tube carcinoma in a BRCA-2 mutation carrier. 54 61
18207147 2008
4
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. 61 54
16835424 2006
5
Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. 61 54
15252324 2004
6
BRCA2 germline mutations in primary cancer of the fallopian tube. 61 54
15254695 2004
7
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. 54 61
15083174 2004
8
Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. 61 54
14984974 2004
9
[Carcinoma of the fallopian tube after prophylactic laparoscopic ovariectomy in a patient with a BRCAI mutation]. 61 54
12756880 2003
10
Incidental diagnosis of primary fallopian tube carcinoma during prophylactic salpingo-oophorectomy in BRCA2 mutation carrier. 54 61
12504983 2002
11
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. 61 54
12354934 2002
12
Pathologic findings in prophylactic oophorectomy specimens in high-risk women. 61 54
12468342 2002
13
Inactivation of BRCA1 and BRCA2 in ovarian cancer. 54 61
12237285 2002
14
Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening. 61 54
11810084 2002
15
A genetic epidemiological study of carcinoma of the fallopian tube. 54 61
11263928 2001
16
Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. 54 61
11161856 2001
17
Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. 61 54
10785486 2000
18
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. 61 54
10620440 2000
19
BRCA1 mutations in familial ovarian cancer. 54 61
10444347 1999
20
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. 61
33743851 2021
21
The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. 61
33650343 2021
22
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report. 61
33377156 2021
23
Concurrent gynecologic surgery and panniculectomy in morbidly obese women with gynecologic cancer, a single-center experience. 61
33740102 2021
24
BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography. 61
33490351 2021
25
The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer. 61
33452952 2021
26
A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer. 61
32776094 2021
27
Case Report: Frontoparietal Metastasis From a Primary Fallopian Tube Carcinoma. 61
33681280 2021
28
Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. 61
32796289 2020
29
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. 61
33037105 2020
30
Collision carcinoma of endometrial adenocarcinoma and primary serous fallopian tube carcinoma: a case report. 61
33203277 2020
31
Clinical characteristics of primary Fallopian tube carcinoma: A single-institution retrospective study of 57 cases. 61
33230808 2020
32
Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years. 61
32709535 2020
33
Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea. 61
32718143 2020
34
Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium. 61
32732252 2020
35
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report. 61
32328861 2020
36
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. 61
32172572 2020
37
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. 61
32811682 2020
38
Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE). 61
32690591 2020
39
Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. 61
32808504 2020
40
To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy. 61
32811236 2020
41
Fallopian Tube Tumor Mimicking Primary Gastrointestinal Malignancy. 61
32953309 2020
42
Paraneoplastic cerebellar degeneration heralding recurrence of fallopian tube adenocarcinoma: A case report and literature review. 61
32904367 2020
43
Incidence trends for epithelial peritoneal, ovarian, and fallopian tube cancer during 1999-2016: a retrospective study based on the Korean National Cancer Incidence Database. 61
32266805 2020
44
Paraneoplastic encephalitis with leukoencephalopathy in primary fallopian tube carcinoma. 61
32395191 2020
45
Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report. 61
32664168 2020
46
Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. 61
32381362 2020
47
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. 61
32527769 2020
48
Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers. 61
32354794 2020
49
MRI can be used to differentiate between primary fallopian tube carcinoma and epithelial ovarian cancer. 61
32160944 2020
50
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. 61
32669924 2020

Variations for Fallopian Tube Carcinoma

Cosmic variations for Fallopian Tube Carcinoma:

9 (show top 50) (show all 683)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM147988734 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2695C>G p.Q899E 9:132897538-132897538 3
2 COSM151335840 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 3
3 COSM111045067 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 3
4 COSM148040940 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2680C>G p.Q894E 9:132897538-132897538 3
5 COSM151876398 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 3
6 COSM150680210 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2683C>G p.Q895E 9:132897538-132897538 3
7 COSM150540031 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2545C>G p.Q849E 9:132897538-132897538 3
8 COSM149044571 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2695C>G p.Q899E 9:132897538-132897538 3
9 COSM85725394 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 3
10 COSM133092250 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2545C>G p.Q849E 9:132897538-132897538 3
11 COSM93207461 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 17:7674202-7674202 3
12 COSM144099306 TP53 endometrium,NS,carcinoma,adenocarcinoma c.-89T>G p.? 17:7675223-7675223 3
13 COSM87905773 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 3
14 COSM112253807 TP53 endometrium,NS,carcinoma,adenocarcinoma c.733G>A p.G245S 17:7674230-7674230 3
15 COSM111761369 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 3
16 COSM142841902 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 3
17 COSM122736483 TP53 ovary,NS,carcinoma,adenocarcinoma c.-2A>G p.? 17:7675217-7675217 3
18 COSM106053540 TP53 endometrium,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 3
19 COSM87925973 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 17:7674202-7674202 3
20 COSM145024458 TP53 ovary,NS,carcinoma,adenocarcinoma c.425G>A p.R142H 17:7675070-7675070 3
21 COSM143157028 TP53 endometrium,NS,carcinoma,adenocarcinoma c.340C>T p.R114C 17:7673803-7673803 3
22 COSM121879352 TP53 ovary,NS,carcinoma,adenocarcinoma c.-2A>G p.? 17:7675217-7675217 3
23 COSM143162603 TP53 endometrium,NS,carcinoma,adenocarcinoma c.217A>G p.I73V 17:7674269-7674269 3
24 COSM142560558 TP53 endometrium,NS,carcinoma,adenocarcinoma c.727C>T p.R243W 17:7673776-7673776 3
25 COSM121901025 TP53 endometrium,NS,carcinoma,adenocarcinoma c.365T>G p.I122S 17:7674202-7674202 3
26 COSM111759017 TP53 endometrium,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 17:7674241-7674241 3
27 COSM122734486 TP53 endometrium,NS,carcinoma,adenocarcinoma c.520C>T p.R174* 17:7673704-7673704 3
28 COSM144100203 TP53 endometrium,NS,carcinoma,adenocarcinoma c.26A>G p.H9R 17:7675109-7675109 3
29 COSM121876472 TP53 endometrium,NS,carcinoma,adenocarcinoma c.448C>T p.R150W 17:7673776-7673776 3
30 COSM93190033 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 3
31 COSM121881481 TP53 endometrium,NS,carcinoma,adenocarcinoma c.445G>A p.D149N 17:7673779-7673779 3
32 COSM106059013 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 3
33 COSM144651436 TP53 endometrium,NS,carcinoma,adenocarcinoma c.625C>T p.R209W 17:7674221-7674221 3
34 COSM143946029 TP53 endometrium,NS,carcinoma,adenocarcinoma c.*43C>T p.? 17:7670685-7670685 3
35 COSM144315389 TP53 ovary,NS,carcinoma,adenocarcinoma c.425G>A p.R142H 17:7675070-7675070 3
36 COSM87917930 TP53 endometrium,NS,carcinoma,adenocarcinoma c.503A>G p.H168R 17:7675109-7675109 3
37 COSM105621213 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 3
38 COSM144087273 TP53 endometrium,NS,carcinoma,adenocarcinoma c.265C>T p.R89W 17:7674221-7674221 3
39 COSM144653327 TP53 endometrium,NS,carcinoma,adenocarcinoma c.*131C>T p.? 17:7670685-7670685 3
40 COSM144675014 TP53 endometrium,NS,carcinoma,adenocarcinoma c.644T>G p.I215S 17:7674202-7674202 3
41 COSM142566974 TP53 endometrium,NS,carcinoma,adenocarcinoma c.577A>G p.I193V 17:7674269-7674269 3
42 COSM143373513 TP53 ovary,NS,carcinoma,adenocarcinoma c.278A>G p.K93R 17:7675217-7675217 3
43 COSM111764887 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 3
44 COSM93185597 TP53 endometrium,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 17:7674894-7674894 3
45 COSM145018055 TP53 endometrium,NS,carcinoma,adenocarcinoma c.799C>T p.R267* 17:7673704-7673704 3
46 COSM142559914 TP53 endometrium,NS,carcinoma,adenocarcinoma c.407G>A p.R136H 17:7675088-7675088 3
47 COSM112253979 TP53 endometrium,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 3
48 COSM143157087 TP53 ovary,NS,carcinoma,adenocarcinoma c.439C>T p.R147* 17:7673704-7673704 3
49 COSM122275678 TP53 endometrium,NS,carcinoma,adenocarcinoma c.445G>A p.D149N 17:7673779-7673779 3
50 COSM143157019 TP53 endometrium,NS,carcinoma,adenocarcinoma c.265C>T p.R89W 17:7674221-7674221 3

Expression for Fallopian Tube Carcinoma

Search GEO for disease gene expression data for Fallopian Tube Carcinoma.

Pathways for Fallopian Tube Carcinoma

Pathways related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 VEGFA TP53 TEAD1 PTEN MYC ESR1
2
Show member pathways
13.78 VEGFA TP53 TEAD1 RAD51D PTEN PGR
3
Show member pathways
13.73 VEGFA TP53 MYC MMP2 ESR1 ERBB2
4
Show member pathways
13.46 TP53 RAD51C MYC MRE11 CDKN1B BRCA2
5
Show member pathways
13.25 TP53 RAD51D RAD51C PALB2 MRE11 BRCA2
6
Show member pathways
13.03 VEGFA TP53 PTEN MYC ERBB2 CDKN1B
7
Show member pathways
13 TP53 RAD51D PTEN MRE11 CDKN1B BRCA1
8
Show member pathways
12.87 TP53 PTEN MYC ESR1 BRCA1 BARD1
9
Show member pathways
12.86 VEGFA TP53 PTEN PAX8 MYC ERBB2
10
Show member pathways
12.67 TP53 MRE11 CDKN1B BRCA1 BARD1
11
Show member pathways
12.66 VEGFA TP53 PTEN MYC ERBB2 CDKN1B
12
Show member pathways
12.64 TP53 MYC MRE11 ESR1 CDKN1B BRCA2
13
Show member pathways
12.64 TP53 PTEN PGR MYC ESR1 ERBB2
14
Show member pathways
12.61 TP53 PTEN MMP2 ESR1 ERBB2 CDKN1B
15 12.58 VEGFA TP53 PTEN PAX8 MYC MMP2
16 12.55 TP53 MRE11 CDKN1B BRCA2 BRCA1
17 12.51 VEGFA TP53 PTEN MYC ERBB2 CDKN1B
18
Show member pathways
12.42 TP53 PTEN MYC MRE11 CDKN1B BRCA1
19
Show member pathways
12.41 TP53 PTEN MYC CDKN1B
20
Show member pathways
12.38 TP53 MRE11 BRCA1 BARD1
21 12.35 VEGFA TP53 MYC MMP2 ESR1 ERBB2
22
Show member pathways
12.33 TP53 PTEN MMP2 ERBB2
23 12.29 TP53 PAX8 MYC CDKN1B
24
Show member pathways
12.27 TP53 PTEN MYC ERBB2 CDKN1B
25
Show member pathways
12.27 PGR MYC ESR1 CDKN1B BRCA1
26 12.22 VEGFA TP53 MYC MMP2
27
Show member pathways
12.21 RAD51D RAD51C PALB2 MRE11 BRCA2 BRCA1
28 12.18 TP53 PTEN MYC MRE11
29 12.04 TP53 PTEN MYC ERBB2 CDKN1B
30 12.03 VEGFA TP53 MYC MMP2
31 12.01 TP53 PTEN MYC CDKN1B
32
Show member pathways
11.98 RAD51D RAD51C PALB2 MRE11 BRCA2 BRCA1
33
Show member pathways
11.93 VEGFA MYC ESR1 ERBB2
34 11.93 RAD51C PALB2 BRCA2 BRCA1
35 11.92 TP53 PTEN MYC CDKN1B
36 11.9 TP53 MYC CDKN1B BARD1
37
Show member pathways
11.84 TP53 MRE11 BRCA1
38
Show member pathways
11.84 TP53 MRE11 BRCA2 BRCA1 BARD1
39 11.78 TP53 PTEN MYC ERBB2
40 11.76 TP53 ERBB2 BRCA1
41 11.76 MYC CDKN1B BRCA1
42 11.76 VEGFA TP53 MYC MMP2 ERBB2
43 11.74 MYC MRE11 ESR1 CDKN1B
44 11.72 PAX8 MYC CDKN1B
45 11.72 MYC ERBB2 CDKN1B
46 11.7 MYC ERBB2 CDKN1B BRCA1
47
Show member pathways
11.67 MYC MMP2 ERBB2 CDKN1B
48 11.67 TP53 PTEN MYC ERBB2 BRCA1
49 11.61 VEGFA TP53 MYC BRCA1
50 11.58 TP53 MYC CDKN1B

GO Terms for Fallopian Tube Carcinoma

Cellular components related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.09 TP53 TEAD1 RAD51D RAD51C PTEN PGR
2 protein-containing complex GO:0032991 9.85 TP53 MYC ESR1 CDKN1B BRCA2 BRCA1
3 nucleoplasm GO:0005654 9.5 TP53 TEAD1 RAD51D RAD51C PTEN PGR
4 BRCA1-A complex GO:0070531 9.4 BRCA1 BARD1
5 Rad51B-Rad51C-Rad51D-XRCC2 complex GO:0033063 9.32 RAD51D RAD51C
6 BRCA1-BARD1 complex GO:0031436 9.26 BRCA1 BARD1
7 replication fork GO:0005657 9.26 TP53 RAD51D RAD51C MRE11

Biological processes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.2 VEGFA TP53 TEAD1 PGR PAX8 MYC
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 VEGFA TP53 TEAD1 PGR PAX8 MYC
3 positive regulation of transcription, DNA-templated GO:0045893 10.05 TP53 TEAD1 PAX8 MYC ESR1 BRCA2
4 positive regulation of gene expression GO:0010628 10.03 VEGFA TP53 PTEN MYC ERBB2 BRCA1
5 regulation of apoptotic process GO:0042981 9.96 TP53 PAX8 ESR1 BRCA1
6 heart development GO:0007507 9.94 TP53 PTEN ERBB2 CDKN1B
7 negative regulation of apoptotic process GO:0043066 9.92 VEGFA TP53 PTEN PALB2 MYC MRE11
8 transcription initiation from RNA polymerase II promoter GO:0006367 9.91 TEAD1 PTEN PGR ESR1
9 DNA repair GO:0006281 9.91 RAD51D RAD51C PALB2 MRE11 BRCA2 BRCA1
10 cell cycle arrest GO:0007050 9.89 TP53 MYC CDKN1B BARD1
11 cellular response to hypoxia GO:0071456 9.88 VEGFA TP53 PTEN MYC
12 regulation of signal transduction by p53 class mediator GO:1901796 9.88 TP53 MRE11 BRCA1 BARD1
13 protein deubiquitination GO:0016579 9.88 TP53 PTEN MYC ESR1 BRCA1 BARD1
14 cellular response to DNA damage stimulus GO:0006974 9.81 TP53 RAD51D RAD51C PALB2 MYC MRE11
15 double-strand break repair via nonhomologous end joining GO:0006303 9.8 MRE11 BRCA1 BARD1
16 positive regulation of epithelial cell proliferation GO:0050679 9.8 VEGFA MYC ERBB2
17 embryonic organ development GO:0048568 9.77 TP53 TEAD1 PALB2
18 double-strand break repair GO:0006302 9.76 TP53 MRE11 BRCA2 BRCA1
19 reciprocal meiotic recombination GO:0007131 9.74 RAD51D RAD51C MRE11
20 DNA recombination GO:0006310 9.73 RAD51D RAD51C PALB2 MRE11 BRCA2 BRCA1
21 response to gamma radiation GO:0010332 9.71 TP53 MYC BRCA2
22 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.67 TP53 BRCA2 BRCA1
23 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.65 TP53 ESR1
24 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.65 TP53 ESR1
25 DNA double-strand break processing GO:0000729 9.65 MRE11 BRCA1 BARD1
26 intracellular steroid hormone receptor signaling pathway GO:0030518 9.64 PGR ESR1
27 protein K6-linked ubiquitination GO:0085020 9.63 BRCA1 BARD1
28 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.62 VEGFA TP53
29 chordate embryonic development GO:0043009 9.61 BRCA2 BRCA1
30 telomere maintenance via recombination GO:0000722 9.61 RAD51D RAD51C BRCA2
31 double-strand break repair via homologous recombination GO:0000724 9.43 RAD51D RAD51C PALB2 MRE11 BRCA2 BRCA1
32 chromosome organization GO:0051276 9.02 TP53 RAD51D MYC MRE11 BRCA2

Molecular functions related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 WFDC2 VEGFA TP53 TEAD1 RAD51D RAD51C
2 identical protein binding GO:0042802 9.81 VEGFA TP53 PTEN PGR MRE11 ESR1
3 DNA-binding transcription factor activity GO:0003700 9.73 TP53 TEAD1 PGR PAX8 MYC ESR1
4 enzyme binding GO:0019899 9.72 TP53 PTEN PGR ESR1 BRCA1
5 protein phosphatase binding GO:0019903 9.58 TP53 ERBB2 CDKN1B
6 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.43 TP53 TEAD1 PGR PAX8 MYC ESR1
7 DNA binding GO:0003677 9.4 TP53 TEAD1 RAD51D RAD51C PGR PAX8

Sources for Fallopian Tube Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....